Intent of the rebuild of the business case
The intent of this rebuild is to turn the financial model from a directional forecast into a more credible, investor-ready planning tool.
The original model showed a promising business opportunity, but some assumptions were too aggressive, some outputs were hardcoded, and the scenarios did not fully flow from a single set of assumptions. That made it harder to test the business properly or defend the numbers under investor scrutiny.
The rebuilt model is designed to make the forecast more transparent, flexible, and evidence-led. It links the scenarios to clear assumptions, models growth through a monthly user funnel, separates B2C and B2B revenue logic, and distinguishes between assumptions supported by market references and assumptions that still need validation through real user data.
The purpose is not to make the numbers look bigger. It is to make them more believable.
A stronger financial model should help answer three investor questions clearly:
- How does NutriSync acquire, convert, and retain users?
- Which assumptions are already supported by market evidence?
- Which assumptions still need to be proven through pilots, waitlist data, retention data, or paid acquisition tests?
By making the Conservative case less aggressive and treating unproven assumptions as validation targets, the model becomes more useful as a decision-making tool. It can now support fundraising conversations, but also help the team identify what must be tested before scaling.
In short, the intent is to move the model from optimistic projection to defensible growth plan.
Three scenarios from one set of assumptions
Formula-linked from the Assumptions tab. End-of-Year-3 outputs (a deliberately less aggressive Conservative case).
| Metric (End of Year 3) | Conservative | Realistic | Ambitious |
|---|---|---|---|
| Total paying users | ~5,870 | ~26,980 | ~93,870 |
| Total annual revenue | ~€316K | ~€1.30M | ~€3.4M+ |
| ARR at year end | ~€379K | ~€1.75M | ~€4.6M+ |
| Gross margin | ~83% | ~83% | ~84% |
| Financing modelled (seed + Series A) | €350K + €1.2M | €350K + €1.8M | €350K + €2.5–6M |
Figures from NUTRISYNC_financial_model_rebuilt.xlsx (Summary tab). Financing inflows are shown separately and are not treated as operating revenue.
What must be proven before pitching assumptions as fact
| Assumption | Original model | Industry reality | Target to prove |
|---|---|---|---|
| Monthly free→paid conversion | 18% flat | 2–7% (top quartile) | ≥3% (conservative) |
| Monthly B2C churn (Y1) | 10% ("conservative") | 12–15% is the true downside; 66% of health apps abandoned in 90 days | Stress-test 12–15% |
| Wearable churn reduction | 50% | Structurally sound (hardware lock-in) | ≥20% reduction in 90-day cohorts |
| Waitlist → paid conversion | 25–42% | High-intent justified, but unproven at scale | Track real waitlist cohort |
| B2B contracts | Smooth scaling | Needs pipeline logic | 2 signed contracts / LOIs |
| AI cost per prompt | — | Can scale faster than revenue | < €0.005/prompt |
Full detail in the Validation Targets tab and the two review documents in the data room above.
Documents
Behind PIN + 2FA. Production access is logged per-file (Cloudflare Access / SSO + MFA).
Healthcare was designed for male biology
Men run on a ~24-hour hormonal cycle; women on ~28 days across four phases. Generic nutrition ignores this — and women pay the cost.
Higher adverse drug reactions
Research & dosing skew male, raising risk for women.
Later diagnoses & delayed care
Women's symptoms are under-recognized and under-served.
Left to self-experiment
No guidance on food + training across cycle phases.
Different biology. Same nutrition?
The "one-size-fits-all" diet ignores the 28-day cycle. NutriSync syncs food & training to each of the four phases.
Menstrual
Iron, warming foods, hydration. Gentle movement & rest.
Follicular
Fresh foods, complex carbs, protein. Build intensity & strength.
Ovulatory
Anti-inflammatory, fiber. Peak performance & HIIT.
Luteal
Magnesium, complex carbs. Steady-state, wind down.
Building scalable women's health infrastructure
Aligned to UN SDG 3 (Good Health & Well-being) and SDG 5 (Gender Equality).
Preventative nutrition
Personalized nutrition aligned with hormonal phases.
Optimization engine
Symptom tracking & optimization engine.
Digital infrastructure
For an underfunded healthcare segment.
Closing the data gap
Real-world cycle data + rising menstrual-health literacy.
The adaptive cycle intelligence
NutriSync transforms menstrual cycle data into actionable, personalized guidance that adapts in real time to your biology and lifestyle. Personalized · science-backed · holistic · private by design.
Cycle Sync Score (CAS)
A real-time 0–100 daily alignment score.
Physiological Biomarker Signals 25%
Nutrition Alignment 30%
Fitness / Recovery Alignment 20%
Logging Consistency 10%
Cycle Stability Score (CSS)
Improvement across cycles, not just today.
Mood Stability Improvement 45%
PMS Symptom Stability 10%
The scoring IP is implemented & unit-tested in packages/core/cas.mjs.
Menstrual health apps market
A fast-growing, specific segment — not the broad FemTech number. Cycle-synced nutrition is the wide-open wedge within it.
TAM
Spain's women's-health app + corporate wellness — everyone who could pay for cycle/hormonal wellbeing tech.
SAM
2M Spanish women already paying for digital health, plus B2B wellness buyers.
SOM
Spain share of the projected 400k users.
Sources: INE 2024 · Heraldo 2023 · Agencia SINC 2023 · European Psychiatry 2022.
From period tracking to cycle nutrition at scale
| What it takes | Generic apps | Content apps | NutriSync |
|---|---|---|---|
| Science-backed cycle-sync framework | ◐ | ◐ | ● |
| Ethical data & privacy design | ◐ | ◐ | ● |
| Integrated cycle, nutrition & fitness plans | ◐ | ◐ | ● |
| AI personalization | — | ◐ | ● |
| Social & community features | ● | ◐ | ● |
| Direct-to-consumer | ● | ● | ● |
| Clinician-partnered distribution | — | — | ● |
| Institutional ATL outreach | — | — | ● |
| TTL data & insight loop | — | — | ● |
On track to launch MVP to 170 beta users in Q3 2026
🔬 Customer validation
160 interviews · 96% report cycle impacts performance · 88% want a personalised solution.
💶 Early revenue
€420+ from paid events · 32+ total paying attendees.
📣 Demand
140+ women waitlist · 30k organic views · university + corporate partnerships.
Backed by IE University, Loadmill, Women in Banking, Bolt.Earth, Viasat.
Four revenue streams
Subscription first, B2B as the multiplier, clinical partnerships as the moat.
B2C Basic — €4.99/mo
Cycle-aware nutrition + fitness plans. Penetration pricing to maximise Y1 volume.
B2C Premium — €12.99/mo
Launches month 13. AI personalised cycle plans + clinical consultation booking. ~160% more revenue per user.
B2B Corporate — €3.99/mo
Corporate wellness contracts. Avg 150 employees = €5,985/yr per contract; renews at €5.99.
Clinical + Events + Brand — €500–8K
Clinic referral fees, paid workshops/masterclasses, and founder brand partnerships.
From waitlist to global platform
Launch & first data · target 3.5K+ users, €20K MRR
Vercel pilot → App Store launch (M3) · CTO hired, first €4.99 subs · paid social from M4 (€3–5k/mo) · Apple HealthKit (M4–6) · AI personalisation engine (M6) · 2 clinical partners signed (B2B pilot) · GDPR health-data architecture.
Active deep tech · target 20K+ users, €80k MRR
Conversational AI companion (M13) · Premium €12.99 live · Oura Ring integration (M15) · predictive hormonal modelling (M20) · UK + Australia + Portugal · 10 B2B, 5 clinical partners · perimenopause tracking.
Hormonal health · target 80K+ users, €200K MRR
CGM integration · at-home hormone test-kit integration · menopause as dedicated product tier · population-health data layer · US launch, AI model matures · academic publication of clinical AI findings.
Founder social
4K followers today → 50K+ by Y3. Zero marginal CAC.
Paid social M4+
€3–5k/mo IG & TikTok · CAC €6–8 (~50% below industry) · 375–625 new users/mo.
B2B & clinical
1 × 150-employee contract = 150 users instantly · 50 patient conversions/clinic/mo · 5 contracts = 750 B2B users Y1.
Events & community
Already revenue-generating · 40–60% convert to subscribers · 2 events = €500–1k/event.
Deck (Conservative) headline figures
Y3 annual revenue
ARR €1.04M annualised.
Y3 paying users
Deep-tech Y2+ impact.
Reach profitability
Breakeven around quarter 11.
Note: the rebuilt financial model (above) deliberately makes the Conservative case less aggressive than these deck figures — ~5.9K paying users / ~€316K revenue by Y3 — and treats unproven assumptions as validation targets. Use the rebuilt model for diligence; the deck figures reflect the prior projection.
Four deep-tech layers, sequenced by funding stage
1 · Adaptive AI engine
Now → M6.
2 · Conversational AI Nutri
M13 (Premium).
3 · Predictive hormonal modelling
Mid-stage.
4 · Lab test + CGM
Series A, Y3.
🛡️ Data moat
3+ months of tracking creates a unique hormonal data signature. Competitors would need ~5 years to build it.
🩺 Clinical moat
Clinical partnerships take 12–18 months; a generic app can't replicate branded clinical content in 6.
📡 Distribution moat
Founder social channels = 50K+ combined audience, zero-marginal-CAC advantage in the exact target demographic.
An Apple Watch becomes a hormonal health advisor — €0 hardware
Access 100M+ existing devices, no hardware to build.
Apple Watch + HealthKit
M4. HR, HRV, sleep, activity, skin temp, blood oxygen. 60% of target own one; API free, 4–6 wks dev.
Google Fit + Wear OS
M4. Spain & Australia (Android 70%+), shared codebase, low marginal cost.
Oura Ring
Y3. Skin-temp trend, HRV readiness, sleep — automatic cycle prediction.
CGM — Dexcom / Libre
Y3. Blood glucose across the cycle; most complete hormonal-nutrition picture.
Menopause — a bigger, almost-empty opportunity
Perimenopause tracking (soft launch)
HRT interaction guidance layer
Menopause as a dedicated product tier + B2B workplace programme
Global menopause market by 2028
7% CAGR. Same infrastructure, different life stage, higher ARPU.
Women entering menopause / yr (US)
Proven demand, almost no tech supply.
App solutions today
Mostly symptom trackers — no integrated nutrition layer.
Join our growth journey
App live & first revenue
4000+ paying users
Seed round closes
Built by women, for women
Pilar Gonzalez
Strategy consulting & research
Lucia Cebrian
UX/UI & product development
Maria Paula Garzon
Branding & marketing strategy
Advisory board
Juan Jose Gonzalez
Technology & Digital Transformation — CTO of CHUBB. Supports digital infrastructure, scalability and AI-driven UX.
Kanika Pandey
AI & Growth Strategy — CRO of Global Sales at Loadmill. Advises on scaling growth.
Clara Miranda
Strategy & Brand Innovation — Former Global Innovation Lead at ING.
Constanza Ramirez Milli
Clinical Nutrition — ensures the nutritional approach is science-based.
Beatriz Serrano Sordo
Finance & Governance — Senior Credit Analyst at AXA. Financial oversight & funding strategy.
NutriSync provides wellness & educational guidance, not medical advice. Confidential — for invited investors, advisors, and team only.